Trial Profile
Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With Sorafenib (BAY 43-9006) in Patients Affected by Relapsed High-grade Osteosarcoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2013
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms HGosteo-BAY
- 05 May 2009 New trial record